Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06547099 · ClinicalTrials.gov registry record
Study to Understand Novel Biomarkers in Researching Dementia
A clinical trial of Alzheimer Disease and Mild Cognitive Impairment, sponsored by Washington University School of Medicine.
- Recruiting
- Registry status
- 1,800
- Enrollment target
- 1
- Study location
NCT06547099 is a study of Alzheimer Disease and Mild Cognitive Impairment that is actively recruiting participants, run by Washington University School of Medicine. The registered enrollment target is 1,800 participants, below the 2,745-participant average among 306 other Alzheimer Disease trials with a reported enrollment target (34% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06547099, a study of Alzheimer Disease and Mild Cognitive Impairment, is actively recruiting participants, sponsored by Washington University School of Medicine.
- RECRUITING
- Registry status
- 1,800 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to determine the relationships between amyloid, tau, and neurodegeneration biomarkers in the blood and the presence of Alzheimer's disease (AD) pathology, clinical cognitive decline, and diagnosis. We aim to understand how well blood-based biomarkers can diagnose and predict Alzheimer's disease, which will help to further develop and validate blood tests for the disease.
Conditions Studied
Interventions
- DIAGNOSTIC_TEST Clinical tau PET
- DIAGNOSTIC_TEST Clinical amyloid test
- OTHER Research blood collection
- OTHER Cognitive assessments
Study Locations (1)
Missouri
- Washington University School of Medicine - St Louis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,800 participants |
| Start Date | 2024-08-14 |
| Est. Completion | 2028-12 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06547099
The ClinicalTrials.gov registry entry for NCT06547099 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 1,800 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,745-participant average among 306 other Alzheimer Disease trials with a reported enrollment target (34% lower). The listed sponsor is Washington University School of Medicine, which has 1,502 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Alzheimer Disease appearing as the primary indexed condition, and to 4 interventions - of which Clinical tau PET is the first listed.
NCT06547099 reports 1 study location spanning 1 distinct geographic area - top geographies include Missouri.
Frequently Asked Questions
What is clinical trial NCT06547099 about?
NCT06547099 is a clinical study titled "Study to Understand Novel Biomarkers in Researching Dementia". The purpose of this study is to determine the relationships between amyloid, tau, and neurodegeneration biomarkers in the blood and the presence of Alzheimer's disease (AD) pathology, clinical cognitive decline, and diagnosis. We aim to understand how well blood-based biomarkers can diagnose and pre...
What is the current status of trial NCT06547099?
This trial is currently recruiting. The enrollment target is 1,800 participants. The study started on 2024-08-14. Estimated completion is 2028-12.
What conditions does trial NCT06547099 study?
This clinical trial studies the following conditions: Alzheimer Disease, Mild Cognitive Impairment, Dementia.
What interventions are being tested in trial NCT06547099?
The interventions under investigation include: Clinical tau PET (DIAGNOSTIC_TEST), Clinical amyloid test (DIAGNOSTIC_TEST), Research blood collection (OTHER), Cognitive assessments (OTHER).
Who is sponsoring clinical trial NCT06547099?
This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06547099 being conducted?
This trial has 1 study location across Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Alzheimer Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-2)
RECRUITING · Phase 3
-
Sex-Specific Effects of Endocrine Disruption on Aging and Alzheimer's Disease
RECRUITING · Phase 4
-
Systemic and Central Inflammation in AD
RECRUITING · Phase 2
-
I-CARE 2: Mobile Telehealth to Reduce Alzheimer'S-related Symptoms
RECRUITING · NA
-
Autologous Activated Adipose-derived Stem Cells (RB-ADSC) Injected Directly Into the Brain for Mild to Moderate Alzheimer's Disease
RECRUITING · Phase 1
-
Cognitive Neurology Unit Clinical Registry
RECRUITING
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.